Using Teriparatide: Combination and Sequential Therapies
Image For Activity Cover
Availability
Registration Required
Expires on Jul 17, 2025
Online Meeting
Jun 17, 2025 1:00 PM - 2:00 PM ET
Cost
Member: $0.00
Non-Member: $45.00
In-Training Member: $0.00
Resident Member: $0.00
Resident Non-Member: $45.00
Credit Offered
1 AMA PRA Category 1 Credit
1 ABIM-MOC Point
1 Participation Credit
  • Course Description
  • Target Audience
  • Learning Objectives
  • Accreditation Statement
  • Faculty and Disclosures
  • Recommended

With the recent removal of its black-box warning and the availability of a generic option, teriparatide is becoming an increasingly viable treatment for patients with osteoporosis. In this focused session, we’ll explore how to effectively integrate teriparatide into treatment plans.. Participants will learn best practices for both sequential and concomitant use of teriparatide with other agents, helping to inform safe and effective decision-making in clinical practice. Don’t miss this opportunity to update your knowledge on one of the most dynamic areas of bone health management.

Format: Live webinar with Q&A session

Physicians-in Practice, Fellows, Pharmacist, Nurse/Nurse Practitioner, Physician Assistant

Upon completion of this webinar, participants will be able to:

  1. Recall the basics of coupling between bone formation and resorption
  2. Summarize bone density response when teriparatide is combined with bisphosphonates
  3. Summarize bone density response when teriparatide is combined with denosumab
  4. Describe bone density response when antiresorptive agent is used after teriparatide
  5. Describe changes in bone density when teriparatide and romosozumab are used sequentially

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

Amal Shibli-Rahhal, MD, MS, MME
Clinical Professor of Internal Medicine-Endocrinology and Metabolism
University of Iowa Hospital and Clinics 

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported no relevant financial relationships:
Amal Shibli-Rahhal, MD, MS, MME

The following member who reviewed content for this activity reported relevant financial relationships:
TBA

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.

 

   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Android App Download IOS App Download Powered By